4507-57-7

Basic information

• Product Name: Methyl-1-aminocyclohexane carboxylate (free base)
• Synonyms: Methyl-1-aminocyclohexane carboxylate (free base);METHYL1-AMINOCYCLOHEXANECARBOXYLATE;Methyl 1-Aminocyclohexanate;Methyl-1-aminocyclohexane carboxylat;Methyl 1-Aminocyclohexanoate;2-aMino-2-Methylcyclohexane-1-carboxylate;cyclohexanecarboxylic acid, 1-aMino-, Methyl ester
• CAS NO: 4507-57-7
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.21
• Product Categories: Amino Acids and Derivatives;Cycloalkanes
• Mol File: 4507-57-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 209.9°C at 760 mmHg
• Flash Point: 79.4°C
• Appearance: /
• Density: 1.047g/cm³
• Vapor Pressure: 0.198mmHg at 25°C
• Refractive Index: 1.472
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.19±0.70(Predicted)
• CAS DataBase Reference: Methyl-1-aminocyclohexane carboxylate (free base)(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-1-aminocyclohexane carboxylate (free base)(4507-57-7)
• EPA Substance Registry System: Methyl-1-aminocyclohexane carboxylate (free base)(4507-57-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 4507-57-7(Hazardous Substances Data)

Usage

General Description

Methyl-1-aminocyclohexane carboxylate (free base) is a chemical compound with a molecular formula C8H15NO2. It is a derivative of cyclohexane and contains an amino group and a carboxylate group. Methyl-1-aminocyclohexane carboxylate (free base) is commonly used as a precursor or intermediate in the synthesis of various pharmaceuticals and organic compounds. It exhibits biological activity as a neurotransmitter or neuromodulator in the brain and central nervous system. Methyl-1-aminocyclohexane carboxylate (free base) has potential applications in medicinal chemistry and drug development due to its ability to influence neurotransmitter activity in the body.

InChI:InChI=1/C8H15NO2/c1-11-7(10)8(9)5-3-2-4-6-8/h2-6,9H2,1H3

Upstream product

• 217299-03-1 4-aminotetrahydro-2H-pyran-4-carboxylic acid hydrochloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 813452-54-9 C₂₃H₂₅NO₄ 
• 2756-85-6 1-aminocyclohexane carboxylic acid 
• 108-94-1 cyclohexanone 
• 702-62-5 spiro(imidazolidine-4,1'-cyclohexane)-2,5-dione 

Downstream Products

• 144876-59-5 methyl 1-isocyanato-1-cyclohexanecarboxylate 
• 847665-26-3 4-{1-[(1-(methoxycarbonyl)cyclohexylcarbamoyl)methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-ylmethyl}-imidazole-1-carboxylic acid tert-butyl ester 
• 256477-68-6 methyl 1-{[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino}cyclohexanecarboxylate 
• 877069-27-7 C₁₈H₃₀N₂O₆ 
• 51972-65-7 Methyl 1-(3,4,5,6-tetrahydrophthalimido)-1-cyclohexanecarboxylate 
• 1188528-69-9 methyl 4-(1-(3,4-dichlorophenylsulfonyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-7-carboxamido)tetrahydro-2H-pyran-4-carboxylate 
• 306768-96-7 (2S)-1-[3-(1-t-butoxycarbonyl-3-methylbutyl)ureido]cyclohexane-1-carboxylic acid methyl ester 
• 797798-56-2 1-(3-Cyclohexyl-ureido)-cyclohexanecarboxylic acid methyl ester 

Relevant articles and documents

PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R1 and R2 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups

Optimization of the amino acid residue within a series of anthranilimide-based glycogen phosphorylase inhibitors is described. These studies culminated in the identification of anthranilimides 16 and 22 which displayed potent in vitro inhibition of GPa in

PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: -N(R7)-, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: -N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: -N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.